4M left in the last quarter and refund is coming from R&D. I assume that there might be some expense from September until now. Now, This is a pharmaceutical shell with around 4-5M asset. Although the trails and the whole key technology were failed, their experience is still here. I guess the fair value for this shell is 0.5-0.6c (just with asset). I will wait and see if they have any new plan. If they can pull out something back to the table or start something new, this will go back at least 1c. All IMO.
FTT Price at posting:
0.2¢ Sentiment: Hold Disclosure: Held
